When someone asks ChatGPT, Gemini or Perplexity about your business, the answer they get is now your first impression. ChatGPT alone reached 900 million weekly active users in February 2026. Traditional online reputation management was built to push bad links off page one. AI visibility and LLM reputation management is about what the answer itself […]

The European Commission proposed today the Digital Fairness Act, a consumer rulebook that would ban loot boxes for minors, blacklist manipulative interface design, and put a termination button on every online subscription. The proposal would repeal the EU’s 2005 Unfair Commercial Practices Directive and replace it with a directly applicable regulation, swapping 27 national rulebooks […]

ByteDance plans to release an AI assistant similar to Meta’s Muse in the coming weeks, Bloomberg reported on Wednesday, citing people familiar with a recent all-hands meeting of the company’s AI team. At that meeting, co-founder Zhang Yiming laid out a sober timeline. He believes ByteDance can compete with Anthropic and OpenAI at the cutting […]

A UK startup developing a radically different type of computer chip has raised $30m in a reported hotly contested funding round.

Cambridge-based Tendrils Compute is looking to challenge the dominance of conventional CPU and GPU architecture. Tendrils is one of several UK chip companies, along with Olix and Fractile, which investors are backing.

Tendrils believes that general-purpose chips based on its computing model, called interaction nets, will scale without the cost diffilculties and historical designed problems linked with current CPUs.

Its technology allows it to run thousands of small processes at the same time and handle complex workloads.

Explaining its tech, Tendrils said: "Instead of starting from a sequential design, we’re building our processor to have thousands of cores operating in parallel. This requires moving beyond the notion of shared mutable memory and linear instruction sequences. To make this possible, we’re working in tandem on the open-source language Vine, which has been designed from the beginning to target a new wave of parallel-first architectures."

The startup has yet to disclose any hardware benchmarks, disclosing its performance levels.

The round was led by Benchmark with participation from Visionaries Clubs, the UK Sovereign AI Fund, FR8, Antimatter, Cloudberry VC, Conviction, Embassy Ventures, and SV Angels.

Revolut Pay is now available as a payment option on Uber, bringing the fintech’s checkout service into one of the world’s most widely used consumer apps. The integration also links rides and deliveries paid through Revolut Pay to the company’s rewards scheme. Moreover, the company says millions of its customers use Uber every month. The main […]

Emerging from stealth, Helsinki-Cambridge biotech startup Switchpoint Bio has raised  $5.3 million in a pre-seed financing round, including a $5 million investment from Treehouse Delmar Investments.

Modern medicines increasingly target precise biological mechanisms, yet once treatment begins, it can be difficult to see how an individual patient’s underlying biology is actually changing and why one patient responds while another does not.

Clinical endpoints can take months or years to read out, tissue biopsies are invasive and difficult to repeat, and conventional blood biomarkers often track outcomes without explaining the biology behind them. 

The company is advancing a new way to measure those changes from blood. Circulating immune cells carry epigenomic marks of disease, exposures and treatment.

Switchpoint Bio combines precision epigenomic profiling and AI to read that record, aiming to give drug developers a scalable view of how disease and treatment change human biology. 

For drug developers, treatment response provides an immediate application: What biology is present before treatment? What changes after a drug is given, by how much, and in what way? What persists despite treatment?

Making those changes measurable over time could provide an earlier and more direct view of mechanism, response and resistance, helping drug developers understand which patients benefit, which do not, and why. 

“Drug developers need to know not only whether a patient responds, but what biology changed, what persisted and why,” said Samuel Myllykangas, PhD, Co-Founder and Chief Executive Officer of Switchpoint Bio.

“Our goal is to make these biological switchpoints visible from a routine blood sample, repeatedly and at the scale required for drug development.”

From deep cellular biology to a scalable blood measurement 

Recent advances in epigenomics, single-cell biology, population-scale datasets and AI are making it possible to connect scalable blood measurements to the underlying cellular biology of disease.  Single-cell multiomic technologies (which analyse multiple types of biological data, such as DNA, RNA and proteins, within individual cells) can provide detailed insights into how cells function.

However, they typically require fresh samples, complex processing and specialised laboratory procedures, making them difficult to use repeatedly across large numbers of patients and at multiple stages of clinical development.

Switchpoint Bio is developing a scalable approach based on targeted DNA methylation profiling directly from blood. Its assay focuses on epigenomically active regions relevant to disease and immune biology, giving deep, cost-efficient coverage of the parts of the methylome that matter most for drug development. 

Built at the intersection of genomics, epigenomics and drug development 

The company was founded by Samuel Myllykangas, PhD, and Jason Buenrostro, PhD, collaborators since developing targeted sequencing technologies together at Stanford University. Buenrostro, a MacArthur Fellow, is a professor at Harvard University, Director of the Epigenomics Program at the Broad Institute of MIT and Harvard, and inventor of ATAC-seq, a foundational epigenomic profiling technology.

Myllykangas previously built and scaled Blueprint Genetics, which was acquired by Quest Diagnostics in 2020. 

They were joined by three co-founders: Niilo Färkkilä, PhD, Chief Commercial Officer, who brings pharmaceutical industry experience from Amgen and GSK; Jussi Paananen, PhD, Chief Technology Officer, who previously served as CTO at Blueprint Genetics; and Mitja Kurki, PhD, Scientific Advisor, who brings experience in population genomics and pharmaceutical data platforms from FinnGen, a nationwide biobank study spanning more than 500,000 participants. Paananen and Kurki have both previously worked as scientists at the Broad Institute of MIT and Harvard. 

The company is now moving from platform development into clinical and industry validation. Switchpoint Bio is testing its approach in autoimmune disease, including systemic lupus erythematosus (SLE), to determine whether it can epigenomically identify disease-relevant immune states from blood and follow them longitudinally through treatment. 

In parallel, Switchpoint Bio is in active discussions with pharmaceutical and biotechnology companies to define its first industry validation programs, with treatment response emerging as a key area of interest. 

“We take a long-term view, backing science we believe can genuinely change how disease is understood and treated,” said Dave Proctor of Treehouse Delmar Investments.

“Switchpoint Bio brings together exceptional scientific talent with a real path to turning breakthrough biology into evidence that helps patients, and we’re proud to support that work.”

  The financing will support continued clinical and industry validation, expansion of the company’s clinical and biobank datasets, further development of its epigenomic and AI platform, and growth of its scientific and technical team across Helsinki and Cambridge. 

Lead image: Switchpoint Bio's founding team. From left: Jussi Paananen, PhD (Chief Technology Officer); Niilo Färkkilä, PhD (Chief Commercial Officer); Samuel Myllykangas, PhD (Chief Executive Officer); Mitja Kurki, PhD (Scientific Advisor); Jason Buenrostro, PhD (Scientific Advisor).

A German unicorn looking to digitise the traditional freight industry today said it had raised €228m in equity and debt, as it looks to expand its network and bolster its technology.

Sennder is a so-called freight forwarder, connecting businesses needing to transport goods by road with available trucking companies. It has raised €73 million in equity from existing investors, led by Scanai, the Swedish transport company, and Poste Italiane, Italy's postal service.

The €155m debt facility is split into three: a €100 million credit facility with Coface, a €40 million facility with the European Investment Bank (EIB) and a €15 million facility with Deutsche Bank.

The new financing follows Berlin-based sennder raising €26 million in 2026. It is unclear what valuation its latest raise was made at. It was last publicly valued at around $2bn in 2022.

Sennder leverages AI, software and data to modernise Europe’s fragmented road freight industry. Shippers use it to find trucks to transport goods across Europe while haulers find loads for their trucks, reducing empty journeys.

Founded in 2015 and headquartered in Berlin, it says it manages more than 150,000 shipments a month.

The funding will be used to support the integration of the European road freight business it bought from US company CH Robinson, which sennder acquired in 2024.

It will also be used to expand its core transport network and the rollout of its technology platform and AI agents to shippers, carriers and other freight companies.

David Nothacker, co-founder and CEO of sennder, said: “Over the past ten years, we have built sennder through innovation and scale. With profitability achieved, we now have the financial flexibility to accelerate our next phase of growth.”

Czech medtech startup Kardi Ai has raised €5.3 million in a Series A funding round led by German HealthTech VC fund Callisto Health, with participation from Česká spořitelna and Slovenská sporiteľňa through Seed Starter, alongside BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels.

Kardi Ai develops a technology platform for long-term heart rhythm monitoring and the early detection of potential heart rhythm disorders. Its solution combines a fitness chest strap equipped with an electrocardiogram (ECG) sensor, a mobile application and AI-powered analysis of ECG recordings.

Traditional cardiac examinations typically capture heart activity over a limited period, potentially missing irregularities that occur intermittently. Kardi Ai aims to address this limitation by enabling patients to monitor their heart rhythm during everyday activities, generating data that can help physicians identify potential problems and determine whether further medical attention is needed. The system does not provide diagnoses but supports clinical decision-making through long-term monitoring and analysis.

In the Czech Republic, Kardi Ai works with more than 70 hospitals and over 20 corporate and employee-benefit partners, with its technology used by more than 6,000 people. According to the company, its monitoring system has identified possible cardiac arrhythmias in approximately one quarter of users, including more than 500 findings classified as critical.

The company has also expanded into Slovakia, where it works with more than 20 physicians, primarily cardiologists, following its market entry several months ago.

Beyond its domestic market, Kardi Ai has established operations in Poland, Romania and Bulgaria, while preparing to enter Germany following the completion of pilot projects. The company has also secured regulatory approvals supporting its planned expansion into India and the United Arab Emirates, and is completing the medical device approval process in Singapore.

We are gradually moving beyond detecting heart rhythm disorders towards technology capable of identifying an increased risk before arrhythmia manifests. Nearly two billion people live in the markets where we already operate or are preparing to launch.
The new capital will allow us to validate this technology at global scale and across patient demographics and pursue our ambition to become a leading provider of long-term ECG monitoring in these markets,

said Vlastimil Hrabal, co-founder and CEO of Kardi Ai.

The new funding will support Kardi Ai's expansion across Europe and Asia, with Germany among its immediate priorities, alongside planned market entries in India, the United Arab Emirates and Singapore.

The company also intends to develop predictive models that analyse data from multiple ECG measurements to estimate the risk of cardiac arrhythmias before they occur. These models remain under development and will require clinical validation and regulatory approval before being introduced into medical practice.

Anthropic has set the terms for the most closely watched listing of the AI era. The Claude maker and some existing shareholders will sell 825 million shares at $70 to $78 each, raising up to $64.4B, with trading due to start on the Nasdaq on November 19 under the ticker ANT. At the top of […]

Some neurons in large language models are rarely activated. Microsoft researchers have found a way to turn fewer than 10 of these dormant neurons into a hidden backdoor, making an otherwise normal AI model behave as expected until it encounters a specific trigger. Once activated, the model can execute malicious commands. The technique, called Lazarus, […]

With what he counts as more than 250 client engagements across agency and embedded in-house roles, Vitalii Khomenko has seen product teams from the inside. Here he makes the case for a new kind of design workflow built for the AI era, and explains why the window to adapt is narrower than most founders think. […]

Over the past 20 years, the technologies used to create digital experiences have evolved dramatically. Yet the process of bringing an idea online has remained largely unchanged.

Marketing and design teams create concepts, define layouts and prepare content that development teams must translate into code before publication. Every new campaign or adaptation can introduce another technical step, affecting delivery times and limiting the autonomy of the teams responsible for the experience.

Artificial intelligence has accelerated code generation, but it has not necessarily removed this dependency. It can make an existing workflow faster without changing its underlying structure.

This raises a broader question for businesses: rather than accelerating the existing process, could the industry rethink why digital experiences still need to be translated into code in the first place?

Design System-to-Market: Rethinking the frontend workflow.

Frontend creation remains fragmented, slow and costly. Disconnected tools, teams and workflows add complexity and limit efficiency, while the frontend remains heavily dependent on hard-coded development.

Although IT teams play an essential role in ensuring performance, security, scalability and governance, not every creative change should require technical intervention. The challenge is to give business teams greater autonomy without compromising the technology behind the experience.

A different approach begins with the design system. Rather than treating it as a reference that developers must interpret and rebuild, the design system can become the foundation from which digital experiences are created, adapted and published.

This is the principle behind Design System-to-Market, the approach introduced by Live Story, the no-code platform developed to help businesses design and publish digital experiences.

The evolution of Live Story builds on the experience gained from working alongside more than 150 enterprise brands across different sectors, from finance to fashion and luxury, including Max Mara Fashion Group, Dolce & Gabbana and Guess.

The model enables marketing, creative and e-commerce teams to work directly with their brand's components, content and visual rules, without requiring a separate development process for every new experience.

AI and human creativity: Moving beyond code generation.

The growing adoption of AI makes this distinction increasingly relevant. AI agents can generate digital interfaces from natural-language prompts, but producing an initial result is only part of the creative process.

Digital experiences must also reflect brand guidelines, adapt to different markets and devices, and accommodate ongoing changes. When every adjustment requires another prompt or round of code generation, creative teams remain dependent on technical processes, adding time and costs.

Live Story approaches this differently. AI agents can generate experiences from prompts, while users can refine individual elements directly through a visual editor, modifying layouts, content and creative details without additional prompts, AI tokens or code.

This allows AI to contribute to the creative process without replacing human judgement. For businesses, it also means AI-generated experiences can remain editable, reusable and consistent with established brand standards.

Design system, components and AI within one platform.

Introduced today, 11 November, the new Live Story brings together the tools needed to turn a creative project into a published digital experience, from campaign and experiential pages to product pages.

At its centre is Live Story Studio, a no-code visual editor that enables teams to start directly from design to create pixel-perfect, responsive digital experiences, manage content independently and adapt pages across different markets, languages and digital touchpoints. Live Story Components allows teams to create reusable components aligned with their design system, providing a shared foundation for creative execution.

Through the Live Story MCP, the platform connects with design tools and AI agents, such as Figma, ChatGPT, Claude and Cursor. Teams can start from existing designs or generate new experiences through natural-language prompts, using their own components and brand rules to guide the creation process. The resulting experiences can then be refined directly in the visual editor, giving teams full control over every change without consuming additional AI tokens or writing code.

Live Story Delivery completes the workflow by publishing these experiences to existing websites, without requiring businesses to replace their technology stack.

“With the new Live Story, we have brought design, AI collaboration and publishing together into a single workflow. Our goal is to overcome the fragmentation that has long slowed down the creation of digital experiences, reducing time-to-market and giving businesses greater agility and control over their frontend,” says Stefano Mocellini, CEO and Founder of Live Story.

The evolution reflects a shift in responsibility: giving the people who understand the brand greater control over its frontend, while IT teams continue to manage the underlying technology. More about this approach and the new platform can be found on the Live Story launch page.

Growth engines: Towards a new generation of digital experiences.

The launch also marks the beginning of a new development phase for Live Story. Among the areas of innovation are growth engines, already being tested in pilot projects with customer brands, opening up new possibilities for interaction, conversation and personalisation.

The vision extends beyond individual web pages towards an ecosystem where design systems, data, content and components provide the foundation for dynamic, brand-consistent digital experiences tailored to each user, with the aim of driving measurable business results through higher conversion rates and revenue growth.

The broader implication is a change in how businesses approach the frontend: not simply as the final technical output of a design process, but as an environment that can be continuously shaped by the teams responsible for the customer experience.

Rather than focusing exclusively on faster code generation, the next phase of frontend innovation may depend on eliminating the need to write code for every new digital experience.

Live Story will explore this approach in a dedicated webinar on 18 November, titled “From brief to live: create digital experiences without the dev queue with Live Story”, examining how design systems, reusable components and AI can support the journey from campaign brief to publication.

The original Starlink Mini was designed to make satellite internet portable, but it still needed an external power source. SpaceX has addressed that limitation with the Starlink Mini 2, announced on Tuesday, which has a detachable battery that clips onto the back of the dish and provides up to 4.5 hours of use. The 71Wh […]

Reddit is turning product discussions on its platform into a dedicated shopping feature. The company introduced Reddit Reviews on Tuesday, a set of AI-generated pages that bring together community conversations about around 10,000 products, with summaries, sentiment breakdowns and links to buy. The feature is rolling out to all US users on iOS, Android and […]

IBM will stop sponsoring work visas and green cards for most positions in IBM Consulting, its largest division, which employs more than 150,000 people and accounts for over half the company’s workforce. The decision comes as the Trump administration tightens restrictions on skilled-worker immigration in the US. Bloomberg first reported the change, citing a document […]

OpenAI has acquired Odessia, an AI travel agent founded by Sonder co-founder Francis Davidson, and shut down the service on the same day. Davidson announced the deal in a post on X on Tuesday, saying he would join OpenAI “to focus on the future of travel”. https://t.co/F3Wq6IJ6rJ — Francis Davidson (@FDavidsonT) November 10, 2026 “I’m […]

Zendesk is changing how businesses pay for its AI, charging them for problems solved rather than for the number of people using the software. The customer service company announced the change on Tuesday at its AI Summit in San Francisco, as part of a new Outcome AI Platform. Under the new plans, customers set an ‘Outcome Budget’ […]